| Literature DB >> 23028920 |
Beate Pesch1, Swaantje Casjens, Ingo Stricker, Daniela Westerwick, Dirk Taeger, Sylvia Rabstein, Thorsten Wiethege, Andrea Tannapfel, Thomas Brüning, Georg Johnen.
Abstract
BACKGROUND: Radon and arsenic are established pulmonary carcinogens. We investigated the association of cumulative exposure to these carcinogens with NOTCH1, HIF1A and other cancer-specific proteins in lung tissue from uranium miners. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2012 PMID: 23028920 PMCID: PMC3444449 DOI: 10.1371/journal.pone.0045305
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of 146 uranium miners in 16 strata defined by exposure to radon (Rn) assessed as working level months (WLM) and arsenic (As) and lung cancer.
| Exposure | Characteristics | Total | Cancer-free | Adeno-carcinoma | Squamous cell carcinoma | Small cell lung cancer |
|
| N | 40 | 10 | 10 | 10 | 10 |
| Age [years] (median, range) | 65, 56–84 | 67, 58–84 | 62, 56–73 | 67, 56–77 | 65, 56–80 | |
| Miners with silicosis | 27 | 9 | 7 | 6 | 5 | |
| Smoking ever/never/missing | 33/1/6 | 8/0/2 | 9/1/0 | 8/0/2 | 8/0/2 | |
| Arsenic [µg/m3 years] | 229 | 236 | 202 | 327 | 189 | |
| Radon [WLM] | 1879 | 1987 | 1763 | 2041 | 1368 | |
| Quartz [mg/m3 years] | 23.9 | 26.6 | 24.4 | 22.6 | 22.7 | |
|
| N | 37 | 10 | 10 | 7 | 10 |
| Age [years] (median, range) | 66, 55–86 | 70, 58–84 | 66, 57–81 | 64, 56–82 | 62, 55–86 | |
| Miners with silicosis | 18 | 8 | 5 | 3 | 2 | |
| Smoking ever/never/missing | 30/2/5 | 8/1/1 | 7/1/2 | 7/0/0 | 8/0/2 | |
| Arsenic [µg/m3 years] | 0 | 0 | 0 | 5 | 9 | |
| Radon [WLM] | 1250 | 1251 | 1270 | 1256 | 1223 | |
| Quartz [mg/m3 years] | 21.9 | 20.2 | 26.8 | 22.3 | 19.0 | |
|
| N | 33 | 10 | 7 | 7 | 9 |
| Age [years] (median, range) | 66, 48–80 | 72, 48–79 | 66, 60–72 | 70, 55–79 | 63, 55–80 | |
| Miners with silicosis | 14 | 4 | 3 | 2 | 5 | |
| Smoking ever/never/missing | 21/5/7 | 7/3/0 | 5/1/1 | 4/0/3 | 5/1/3 | |
| Arsenic [µg/m3 years] | 188 | 189 | 188 | 159 | 234 | |
| Radon [WLM] | 173 | 63 | 151 | 193 | 182 | |
| Quartz [mg/m3 years] | 11.7 | 13.5 | 9.7 | 11.2 | 11.7 | |
|
| N | 36 | 9 | 8 | 9 | 10 |
| Age [years] (median, range) | 67, 50–87 | 75, 50–87 | 62, 51–73 | 67, 58–79 | 71, 52–82 | |
| Miners with silicosis | 6 | 4 | 0 | 0 | 2 | |
| Smoking ever/never/missing | 27/0/9 | 5/0/4 | 6/0/2 | 7/0/2 | 9/0/1 | |
| Arsenic [µg/m3 years] | 0 | 0 | 0 | 0 | 0 | |
| Radon [WLM] | 54 | 255 | 91 | 58 | 21 | |
| Quartz [mg/m3 years] | 5.0 | 4.8 | 9.8 | 5.3 | 4.9 | |
|
| N | 146 | 39 | 35 | 33 | 39 |
| Age [years] (median, range) | 66, 48–87 | 72, 48–87 | 63, 51–81 | 67, 55–82 | 65, 52–86 | |
| Miners with silicosis | 65 | 25 | 15 | 11 | 14 | |
| Smoking ever/never/missing | 111/8/27 | 28/4/7 | 27/3/5 | 26/0/7 | 30/1/8 | |
| Arsenic [µg/m3 years] | 75.5 | 109.2 | 44.5 | 104.6 | 48.0 | |
| Radon [WLM] | 1044 | 1042 | 1189 | 1075 | 1022 | |
| Quartz [mg/m3 years] | 16.3 | 17.7 | 17.3 | 18.2 | 13.8 |
Spearman correlation coefficients between marker scores in 146 samples of lung tissue.
| HIF1A (cytoplasm) | MUC1 (membrane) | NKX2-1 (nucleus) | NOTCH1 (cytoplasm) | |||||
| Marker | rS | 95% CI | rS | 95% CI | rS | 95% CI | rS | 95% CI |
| CCND1 (nucleus) | 0.69 | (0.59;0.77) | −0.07 | (−0.23;0.10) | −0.34 | (−0.48; −0.19) | 0.72 | (0.63;0.79) |
| CCND1 (cytoplasm) | 0.73 | (0.64;0.80) | −0.27 | (−0.42; −0.12) | −0.45 | (−0.57; −0.31) | 0.78 | (0.70;0.83) |
| CD44 (membrane) | 0.58 | (0.46;0.68) | −0.08 | (−0.24;0.08) | −0.52 | (−0.63; −0.39) | 0.47 | (0.33;0.59) |
| CD44 (cytoplasm) | 0.56 | (0.43;0.66) | −0.13 | (−0.28;0.04) | −0.45 | (−0.57; −0.31) | 0.48 | (0.34;0.59) |
| CDH1 (membrane) | 0.74 | (0.66;0.81) | −0.15 | (−0.30;0.01) | −0.43 | (−0.55; −0.28) | 0.68 | (0.58;0.76) |
| CDH1 (cytoplasm) | 0.45 | (0.31;0.57) | −0.37 | (−0.50; −0.22) | −0.44 | (−0.56; −0.29) | 0.45 | (0.31;0.57) |
| CTNNB1 (membrane) | 0.79 | (0.72;0.84) | −0.05 | (−0.21;0.11) | −0.40 | (−0.53; −0.25) | 0.74 | (0.65;0.80) |
| CTNNB1 (cytoplasm) | 0.56 | (0.44;0.66) | −0.08 | (−0.24;0.09) | −0.18 | (−0.33; −0.01) | 0.53 | (0.40;0.64) |
| EGFR (membrane) | 0.69 | (0.59;0.77) | −0.08 | (−0.24;0.08) | −0.50 | (−0.61; −0.37) | 0.68 | (0.58;0.76) |
| EGFR (cytoplasm) | 0.68 | (0.58;0.75) | −0.17 | (−0.32;0.00) | −0.46 | (−0.58; −0.32) | 0.70 | (0.61;0.78) |
| ERBB2 (cytoplasm) | 0.58 | (0.46;0.68) | −0.10 | (−0.25;0.07) | −0.30 | (−0.44; −0.14) | 0.68 | (0.58;0.76) |
|
| 1.00 | 0.15 | (−0.02;0.30) | −0.17 | (−0.33; −0.01) | 0.73 | (0.65;0.80) | |
| KIT (cytoplasm) | 0.41 | (0.27;0.54) | −0.30 | (−0.44; −0.14) | −0.25 | (−0.40; −0.10) | 0.47 | (0.33;0.58) |
| KRT14 (membrane) | 0.41 | (0.27;0.54) | 0.01 | (−0.16;0.17) | −0.52 | (−0.63; −0.38) | 0.38 | (0.23;0.51) |
| KRT14 (cytoplasm) | 0.51 | (0.38;0.62) | −0.01 | (−0.17;0.16) | −0.45 | (−0.57; −0.31) | 0.47 | (0.33;0.59) |
| KRT5 (membrane) | 0.51 | (0.38;0.62) | −0.08 | (−0.24;0.08) | −0.61 | (−0.70; −0.49) | 0.47 | (0.33;0.59) |
| KRT5 (cytoplasm) | 0.57 | (0.45;0.67) | −0.06 | (−0.22;0.10) | −0.59 | (−0.68; −0.47) | 0.54 | (0.41;0.64) |
| MMP2 (cytoplasm) | 0.64 | (0.53;0.73) | 0.16 | (0.00;0.31) | −0.07 | (−0.23;0.09) | 0.58 | (0.46;0.68) |
|
| 0.15 | (−0.02;0.30) | 1.00 | 0.58 | (0.46;0.68) | −0.09 | (−0.25;0.08) | |
| MUC1 (cytoplasm) | −0.01 | (−0.17;0.15) | 0.68 | (0.57;0.75) | 0.70 | (0.60;0.77) | −0.13 | (−0.28;0.04) |
|
| −0.17 | (−0.33; −0.01) | 0.58 | (0.46;0.68) | 1.00 | −0.31 | (−0.45; −0.15) | |
|
| 0.73 | (0.65;0.80) | −0.09 | (−0.25;0.08) | −0.31 | (−0.45; −0.15) | ||
| PAK1 (nucleus) | 0.36 | (0.20;0.49) | −0.27 | (−0.41; −0.11) | −0.29 | (−0.43; −0.14) | 0.49 | (0.35;0.60) |
| PTGS2 (cytoplasm) | 0.75 | (0.66;0.81) | −0.11 | (−0.27;0.05) | −0.31 | (−0.45; −0.16) | 0.71 | (0.62;0.78) |
| SFTPC (cytoplasm) | 0.84 | (0.78;0.88) | 0.35 | (0.19;0.48) | −0.04 | (−0.20;0.12) | 0.68 | (0.58;0.76) |
| SNAI1 (nucleus) | 0.43 | (0.29;0.55) | −0.41 | (−0.54; −0.26) | −0.38 | (−0.51; −0.23) | 0.45 | (0.31;0.57) |
| SNAI1 (cytoplasm) | 0.33 | (0.18;0.47) | −0.08 | (−0.24;0.08) | −0.16 | (−0.32;0.00) | 0.40 | (0.25;0.52) |
| STAT3 (nucleus) | 0.22 | (0.06;0.37) | 0.11 | (−0.06;0.26) | −0.11 | (−0.27;0.05) | 0.09 | (−0.07;0.25) |
| STAT3 (cytoplasm) | 0.64 | (0.53;0.72) | 0.17 | (0.00;0.32) | −0.02 | (−0.18;0.14) | 0.55 | (0.42;0.65) |
| TP53 (nucleus) | 0.34 | (0.18;0.47) | −0.30 | (−0.44; −0.14) | −0.34 | (−0.48; −0.19) | 0.37 | (0.22;0.50) |
| TP53 (cytoplasm) | 0.30 | (0.14;0.44) | −0.10 | (−0.25;0.07) | −0.03 | (−0.19;0.13) | 0.24 | (0.08;0.38) |
| VEGFA (cytoplasm) | 0.55 | (0.42;0.65) | −0.38 | (−0.51; −0.23) | −0.33 | (−0.47; −0.18) | 0.55 | (0.42;0.65) |
| VIM (membrane) | 0.38 | (0.23;0.51) | 0.01 | (−0.15;0.18) | −0.20 | (−0.35; −0.04) | 0.31 | (0.15;0.45) |
| VIM (cytoplasm) | 0.34 | (0.18;0.47) | 0.02 | (−0.14;0.19) | −0.08 | (−0.24;0.09) | 0.36 | (0.21;0.49) |
Spearman correlation coefficients of selected marker scores with cumulative exposure to radon and arsenic in lung tissue from 146 uranium miners.
| Exposure | NOTCH1 (cytoplasm) | HIF1A (cytoplasm) | MUC1 (membrane) | NKX2-1 (nucleus) | |||||
| rS | 95% CI | rS | 95% CI | rS | 95% CI | rS | 95% CI | ||
| All (N = 146) | Radon | 0.18 | (0.02;0.33) | 0.12 | (−0.04;0.28) | 0.03 | (−0.13;0.19) | 0.07 | (−0.10;0.23) |
| Arsenic | 0.23 | (0.07;0.38) | 0.03 | (−0.13;0.19) | 0.00 | (−0.16;0.16) | 0.01 | (−0.15;0.17) | |
| Lung cancer (N = 107) | Radon | 0.26 | (0.07;0.42) | 0.12 | (−0.07;0.30) | 0.07 | (−0.12;0.26) | 0.11 | (−0.08;0.29) |
| Arsenic | 0.34 | (0.16;0.49) | 0.02 | (−0.17;0.21) | 0.06 | (−0.14;0.24) | 0.00 | (−0.19;0.19) | |
| Adenocarcinoma (N = 35) | Radon | 0.31 | (−0.03;0.58) | 0.13 | (−0.21;0.44) | 0.16 | (−0.18;0.47) | −0.07 | (−0.39;0.27) |
| Arsenic | 0.73 | (0.51;0.85) | 0.05 | (−0.29;0.37) | 0.11 | (−0.23;0.43) | −0.04 | (−0.36;0.30) | |
| Squamous cell carcinoma (N = 33) | Radon | 0.34 | (−0.01;0.61) | −0.06 | (−0.40;0.29) | 0.10 | (−0.26;0.42) | – | |
| Arsenic | 0.25 | (−0.11;0.54) | −0.05 | (−0.39;0.30) | −0.03 | (−0.37;0.32) | – | ||
| Small cell lung cancer (N = 39) | Radon | 0.22 | (−0.10;0.50) | 0.21 | (−0.11;0.49) | −0.20 | (−0.48;0.13) | 0.46 | (0.16;0.67) |
| Arsenic | 0.28 | (−0.05;0.54) | 0.00 | (−0.31;0.32) | 0.16 | (−0.16;0.45) | 0.14 | (−0.19;0.43) | |
| Cancer-free samples (N = 39) | Radon | −0.12 | (−0.42;0.20) | 0.10 | (−0.22;0.40) | 0.12 | (−0.20;0.42) | 0.17 | (−0.16;0.46) |
| Arsenic | −0.12 | (−0.42;0.20) | 0.03 | (−0.29;0.34) | −0.32 | (−0.57;0.00) | 0.17 | (−0.16;0.46) | |
Proportion of lung tissue samples with positive staining of candidate proteins in lung cancer tissue and in cancer-free samples from uranium miners.
| Adenocarcinoma (N = 35) | Squamous cell carcinoma (N = 33) | Small cell lung cancer (N = 39) | Cancer-free (N = 39) | |||||||||
| Membrane | Cytoplasm | Nucleus | Membrane | Cytoplasm | Nucleus | Membrane | Cytoplasm | Nucleus | Membrane | Cytoplasm | Nucleus | |
|
| 0 | 33 (94%) | 28 (80%) | 4 (12%) | 33 (100%) | 27 (82%) | 0 | 31 (79%) | 1 (3%) | 0 | 2 (5%) | 0 |
|
| 15 (43%) | 17 (49%) | 0 | 29 (88%) | 28 (85%) | 0 | 2 (5%) | 4 (10%) | 0 | 0 | 0 | 0 |
|
| 32 (91%) | 28 (80%) | 0 | 33 (100%) | 33 (100%) | 0 | 15 (38%) | 21 (54%) | 0 | 0 | 0 | 0 |
|
| 31 (89%) | 29 (83%) | 1 (3%) | 32 (97%) | 30 (91%) | 0 | 6 (15%) | 19 (49%) | 0 | 0 | 18 (46%) | 0 |
|
| 27 (77%) | 31 (89%) | 0 | 33 (100%) | 33 (100%) | 0 | 7 (18%) | 14 (36%) | 0 | 0 | 0 | 0 |
|
| 1 (3%) | 23 (66%) | 0 | 0 | 25 (76%) | 0 | 0 | 10 (26%) | 0 | 0 | 0 | 0 |
|
| 0 | 35 (100%) | 0 | 0 | 33 (100%) | 0 | 0 | 22 (56%) | 0 | 0 | 35 (90%) | 3 (8%) |
|
| 3 (9%) | 24 (69%) | 0 | 0 | 23 (70%) | 0 | 0 | 21 (54%) | 0 | 0 | 0 | 0 |
|
| 5 (14%) | 9 (26%) | 0 | 32 (97%) | 33 (100%) | 0 | 1 (3%) | 1 (3%) | 0 | 0 | 0 | 0 |
|
| 1 (3%) | 8 (23%) | 0 | 22 (67%) | 23 (70%) | 0 | 1 (3%) | 3 (8%) | 0 | 0 | 0 | 0 |
|
| 0 | 27 (77%) | 0 | 0 | 24 (73%) | 0 | 0 | 2 (5%) | 0 | 0 | 16 (41%) | 0 |
|
| 29 (83%) | 34 (97%) | 0 | 32 (97%) | 33 (100%) | 0 | 4 (10%) | 37 (95%) | 0 | 39 (100%) | 39 (100%) | 0 |
|
| 0 | 0 | 35 (100%) | 0 | 0 | 0 | 0 | 0 | 29 (74%) | 0 | 0 | 39 (100%) |
|
| 0 | 29 (83%) | 1 (3%) | 0 | 31 (94%) | 3 (9%) | 0 | 10 (26%) | 0 | 0 | 4 (10%) | 0 |
|
| 0 | 7 (20%) | 23 (66%) | 0 | 2 (6%) | 22 (67%) | 0 | 1 (3%) | 17 (44%) | 0 | 0 | 0 |
|
| 1 (3%) | 31 (89%) | 0 | 0 | 30 (91%) | 1 (3%) | 0 | 10 (26%) | 0 | 0 | 0 | 0 |
|
| 0 | 33 (94%) | 1 (3%) | 0 | 33 (100%) | 0 | 0 | 7 (18%) | 0 | 0 | 38 (97%) | 0 |
|
| 0 | 8 (23%) | 35 (100%) | 0 | 9 (27%) | 30 (91%) | 0 | 3 (8%) | 28 (72%) | 0 | 0 | 2 (5%) |
|
| 0 | 29 (83%) | 6 (17%) | 0 | 32 (97%) | 14 (42%) | 0 | 25 (64%) | 3 (8%) | 0 | 39 (100%) | 10 (26%) |
|
| 0 | 9 (26%) | 34 (97%) | 0 | 6 (18%) | 32 (97%) | 0 | 5 (13%) | 34 (87%) | 0 | 0 | 27 (69%) |
|
| 0 | 34 (97%) | 2 (6%) | 0 | 33 (100%) | 3 (9%) | 0 | 29 (74%) | 2 (5%) | 2 (5%) | 6 (15%) | 0 |
|
| 6 (17%) | 12 (34%) | 0 | 8 (24%) | 11 (33%) | 0 | 0 | 5 (13%) | 0 | 0 | 3 (8%) | 0 |
Figure 1Classification and regression tree with leave-one-out cross-validation for cancer-free lung tissue, adenocarcinoma (AdCa), squamous cell carcinoma (SqCC), and small cell cancer of the lung (SCLC).
using immunohistochemical scores of 22 candidate proteins in 146 tissue samples from uranium miners. Staining of mucin 1 (MUC1) in the membrane, hypoxia-inducible factor 1 α (HIF1A) in the cytoplasm, and NK2 homeobox 1 (NKX2-1) in the nucleus resulted in a three-protein classifier with a failure rate of 11.0%.
Figure 2Cluster analysis of major subtypes of lung cancer in 107 tissue samples from uranium miners using average linkage and Euclidian distance for immunohistochemical scores of hypoxia-inducible factor 1 α (HIF1A) in the cytoplasm and NKX2-1 in the nucleus.